Minerva Surgical, Inc. v. Hologic, Inc. | |
---|---|
Argued April 21, 2021 Decided June 29, 2021 | |
Full case name | Minerva Surgical, Inc. v. Hologic, Inc. |
Citations | 594 U.S. ___ ( more ) |
Case history | |
Prior | Decided for Hologic in the United States District Court for the District of Delaware. Appealed to the United States Circuit Court for the Federal Circuit, decision of the District Court affirmed and vacated in part. |
Holding | |
Assignor estoppel is a recognized principle, however it only applies when a claim of invalidity is actually inconsistent with representations of the patents validity. | |
Court membership | |
| |
Case opinions | |
Majority | Kagan, joined by Roberts, Breyer, Sotomayor, Kavanaugh |
Dissent | Alito |
Dissent | Barrett, joined by Thomas, Gorsuch |
Minerva Surgical, Inc. v. Hologic, Inc., 594 U.S. ___ (2021), was a United States Supreme Court case dealing with the principle of assignor estoppel and its application. The Supreme Court reaffirmed the principle of assignor estoppel, however with the exception that the doctrine is only applied when assignors assertions are actually consistent with previous representations as to the patent. The majority decision was written by Justice Elena Kagan, with Justice Samuel Alito and Justice Amy Coney Barrett filing separate dissenting opinions.
Csaba Truckai founded the company NovaCept, which invented the NovaSure medical system, which detects perforations in the uterus through the usage of Carbon Dioxide gas. NovaCept was acquired by Cytyc Corporation in 2004, which was then acquired by Hologic in 2007. Hologic received U.S. Patents 6,872,183 and 9,095,348 in 2005 and 2015 respectively. [1] [2] Truckai left NovaCept to found his own company, Minerva, Inc. and received permission to commercially distribute an Endometrial Ablation System.
Hologic, Inc. sued Minerva, Inc. for violations of U.S. Patents 6,872,183 and 9,095,348, both relating to the procedure of endometrial ablation, for the treatment of menorrhagia. Minerva argued that the patents were invalid in the first place, and challenged the patentability of both patents in the U.S. Patent Office. Hologic moved for summary judgement arguing the principle of assignor estoppel, which was granted. The jury awarded $4.7 million in damages to Hologic. Both Minerva and Hologic appealed for differing reasons. On Appeal to the Federal circuit, Minerva asked the court to "abandon the doctrine" of assignor estoppel on the basis that the doctrine is invalidated due to the Supreme Court abolishing the doctrine of licensee estoppel in Lear, Inc. v. Adkins, 395 U.S. 653 (1969), although the Federal Circuit Court rejected this argument. Minerva Surgical, Inc. filed a petition for a writ of certiorari on September 30, 2020.
See main article: Assignor estoppel
Assignor estoppel is a legal doctrine that states that a claim of invalidity cannot be taken by a person who sells a patent (assignor). The doctrine was first recognized in the United States in Westinghouse Elec & Mfg. Co. v. Formica Insulation Co., 266 U.S. 342 (1924.)
In a 5–4 decision, the Supreme Court re-affirmed the principle of assignor estoppel, and rejected the argument of Minerva that the doctrine was repealed through the Patent Act of 1952. Writing for the majority, Justice Kagan wrote that "[assignor estoppel] applies when, but only when, the assignor's claim of invalidity contradicts explicit or implicit representations he made in assigning the patent."
Justice Barrett argued in the principal dissent that the Patent Act of 1952 precludes the principle of Assignor estoppel. Justice Alito, who also wrote a dissenting opinion, argued that neither the principal dissent nor the majority opinion are valid as neither answered the question as to whether Westinghouse Elec. & Mfg. Co. v. Formica Insulation Co., 266 U. S. 342 (1924) should be upheld or overruled.
Estoppel is a judicial device in common law legal systems whereby a court may prevent or "estop" a person from making assertions or from going back on his or her word; the person being sanctioned is "estopped". Estoppel may prevent someone from bringing a particular claim. Legal doctrines of estoppel are based in both common law and equity. It is also a concept in international law.
In United States patent law, patent misuse is a patent holder's use of a patent to restrain trade beyond enforcing the exclusive rights that a lawfully obtained patent provides. If a court finds that a patent holder committed patent misuse, the court may rule that the patent holder has lost the right to enforce the patent. Patent misuse that restrains economic competition substantially can also violate United States antitrust law.
The doctrine of assignor estoppel is a doctrine of United States patent law barring a patent's seller (assignor) from attacking the patent's validity in subsequent patent infringement litigation. The doctrine is based on the doctrine of legal estoppel, which prohibits a grantor from challenging the validity of his/her/its grant.
Festo Corp. v Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002), was a United States Supreme Court decision in the area of patent law that examined the relationship between the doctrine of equivalents and the doctrine of prosecution history estoppel.
LabCorp v. Metabolite, Inc., 548 U.S. 124 (2006), is the first case since Diamond v. Chakrabarty in which the U.S. Supreme Court indicated a renewed interest in examining the limits of patentable subject matter for advances in life sciences. Although the Court initially agreed to hear the case, it was later dismissed in 2006 with three Justices dissenting. The defendant's petition to the Supreme Court raised an issue not addressed in opinions from the lower courts: the claim at issue was directed to patent ineligible subject matter and therefore invalid.
Lear, Inc. v. Adkins, 395 U.S. 653 (1969), is a decision of the U.S. Supreme Court overturning the doctrine of licensee estoppel and holding that public interest considerations require that licensees be free to challenge the validity of possibly spurious patents under which they are licensed. This entailed the overruling of Automatic Radio Mfg. Co. v. Hazeltine Research, Inc. and prior cases that it had reaffirmed.
Licensee estoppel is a doctrine under which a licensee of an intellectual property right, generally a patent or a trademark, is estopped from challenging the validity of the licensed property. The basis for the doctrine is the premise that a licensee should not be able to enjoy the benefit of an agreement and at the same time attack the validity of the intellectual property that forms the basis of the agreement.
United States v. Glaxo Group Ltd., 410 U.S. 52 (1973), is a 1973 decision of the United States Supreme Court in which the Court held that (1) when a patent is directly involved in an antitrust violation, the Government may challenge the validity of the patent; and (2) ordinarily, in patent-antitrust cases, "[m]andatory selling on specified terms and compulsory patent licensing at reasonable charges are recognized antitrust remedies."
Legal estoppel is a principle of law, particularly United States patent law, that an assignor or grantor is not permitted subsequently to deny the validity of title to the subject matter of the assignment or grant. Originally a principle of real property law, applicable to deeds of land and called estoppel by deed, the Supreme Court extended legal estoppel to patents in Westinghouse Elec. & Mfg. Co. v. Formica Insulation Co.
The doctrine of non-derogation from grants is a principle of the law of England and Wales. As the House of Lords explained in British Leyland Motor Corp. v. Armstrong Patents Co., it states that a seller of realty or goods is not permitted to take any action that will lessen the value to the buyer of the thing sold.
The Journal of the Patent and Trademark Office Society is a quarterly peer-reviewed law journal covering intellectual property law. It was established in 1918.
Kirtsaeng v. John Wiley & Sons, Inc., 568 U.S. 519 (2013), is a United States Supreme Court copyright decision in which the Court held, 6–3, that the first-sale doctrine applies to copies of copyrighted works lawfully made abroad.
Evans v. Eaton, 20 U.S. 356 (1822), was a United States Supreme Court case in which the Court held, chiefly, that a patent on an improved machine must clearly describe how the machine differs from the prior art.
Kimble v. Marvel Entertainment, LLC, 576 U.S. 446 (2015), is a significant decision of the United States Supreme Court for several reasons. One is that the Court turned back a considerable amount of academic criticism of both the patent misuse doctrine as developed by the Supreme Court and the particular legal principle at issue in the case. Another is that the Court firmly rejected efforts to assimilate the patent misuse doctrine to antitrust law and explained in some detail the different policies at work in the two bodies of law. Finally, the majority and dissenting opinions informatively articulate two opposing views of the proper role of the doctrine of stare decisis in US law.
Henry v. A.B. Dick Co., 224 U.S. 1 (1912), was a 1912 decision of the United States Supreme Court that upheld patent licensing restrictions such as tie-ins on the basis of the so-called inherency doctrine—the theory that it was the inherent right of a patent owner, because he could lawfully refuse to license his patent at all, to exercise the "lesser" right to license it on any terms and conditions he chose. In 1917, the Supreme Court overruled the A.B. Dick case in Motion Picture Patents Co. v. Universal Film Mfg. Co.,
The reverse doctrine of equivalents is a legal doctrine of United States patent law, according to which a device that appears to literally infringe a patent claim, by including elements or limitations that correspond to each element or limitation of the patent claim, nonetheless does not infringe the patent, because the accused device operates on a different principle. That is, "it performs the same or a similar function in a substantially different way." It has been said that "the purpose of the 'reverse' doctrine is to prevent unwarranted extension of the claims beyond a fair scope of the patentee's invention."
Pope Mfg. Co. v. Gormully, 144 U.S. 224 (1892), was an early United States Supreme Court decision refusing, on public policy grounds, to enforce an agreement not to contest patent validity. The Supreme Court later relied on Pope in Lear, Inc. v. Adkins as authority in support of overruling the doctrine of licensee estoppel. That doctrine had prohibited patent licensees from challenging the validity of patents under which they had been licensed.
Blonder-Tongue Labs., Inc. v. University of Ill. Foundation, 402 U.S. 313 (1971), is a decision of the United States Supreme Court holding that a final judgment in an infringement suit against a first defendant that a patent is invalid bars the patentee from relitigating the same patent against other defendants. In so ruling, the Supreme Court overruled its 1936 decision in Triplett v. Lowell, which had required mutuality of estoppel to bar such preclusion, and held that the better view was to prevent relitigating if the plaintiff had had a full and fair opportunity to litigate the issue in question.
SAS Institute Inc. v. Iancu, 584 U.S. ___ (2018), was a United States Supreme Court case in which the Court held the United States Patent and Trademark Office, when conducting an inter partes review, must make judgement on all patent claims contested by the petitioner.
United States v. Arthrex, Inc., 594 U.S. ___ (2021), was a United States Supreme Court case related to the Appointments Clause of the United States Constitution as it related to patent judges on the Patent Trial and Appeal Board (PTAB). In a complex decision, the Court ruled that these judges were considered "primary officers" under the Appointments Clause, normally subject to appointment through the US President and the US Senate, but to remedy the matter, the Court ruled that the constitutional issue is resolved by allowing the PTAB decisions to be subject to review by the appropriately-appointed Director of the Patent Office.